202 related articles for article (PubMed ID: 30709841)
1. Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer.
Lo W; Parkhurst M; Robbins PF; Tran E; Lu YC; Jia L; Gartner JJ; Pasetto A; Deniger D; Malekzadeh P; Shelton TE; Prickett T; Ray S; Kivitz S; Paria BC; Kriley I; Schrump DS; Rosenberg SA
Cancer Immunol Res; 2019 Apr; 7(4):534-543. PubMed ID: 30709841
[TBL] [Abstract][Full Text] [Related]
2. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.
Kim SP; Vale NR; Zacharakis N; Krishna S; Yu Z; Gasmi B; Gartner JJ; Sindiri S; Malekzadeh P; Deniger DC; Lowery FJ; Parkhurst MR; Ngo LT; Ray S; Li YF; Hill V; Florentin M; Masi RV; Paria BC; Levin N; Bera A; Hedges EA; Choi A; Chatani PD; Parikh AY; Levi S; Seitter S; Lu YC; Zheng Z; Prickett TD; Jia L; Hernandez JM; Hoang CD; Robbins PF; Goff SL; Sherry RM; Yang JC; Rosenberg SA
Cancer Immunol Res; 2022 Aug; 10(8):932-946. PubMed ID: 35749374
[TBL] [Abstract][Full Text] [Related]
3. T-cell Responses to
Deniger DC; Pasetto A; Robbins PF; Gartner JJ; Prickett TD; Paria BC; Malekzadeh P; Jia L; Yossef R; Langhan MM; Wunderlich JR; Danforth DN; Somerville RPT; Rosenberg SA
Clin Cancer Res; 2018 Nov; 24(22):5562-5573. PubMed ID: 29853601
[No Abstract] [Full Text] [Related]
4. Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens.
Malekzadeh P; Yossef R; Cafri G; Paria BC; Lowery FJ; Jafferji M; Good ML; Sachs A; Copeland AR; Kim SP; Kivitz S; Parkhurst MR; Robbins PF; Ray S; Xi L; Raffeld M; Yu Z; Restifo NP; Somerville RPT; Rosenberg SA; Deniger DC
Clin Cancer Res; 2020 Mar; 26(6):1267-1276. PubMed ID: 31996390
[TBL] [Abstract][Full Text] [Related]
5. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
[TBL] [Abstract][Full Text] [Related]
6. T cell receptors employ diverse strategies to target a p53 cancer neoantigen.
Wu D; Gowathaman R; Pierce BG; Mariuzza RA
J Biol Chem; 2022 Mar; 298(3):101684. PubMed ID: 35124005
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen.
Wu D; Gallagher DT; Gowthaman R; Pierce BG; Mariuzza RA
Nat Commun; 2020 Jun; 11(1):2908. PubMed ID: 32518267
[TBL] [Abstract][Full Text] [Related]
8. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
[TBL] [Abstract][Full Text] [Related]
9. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
[TBL] [Abstract][Full Text] [Related]
10. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
[No Abstract] [Full Text] [Related]
11. Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes.
Gee MH; Han A; Lofgren SM; Beausang JF; Mendoza JL; Birnbaum ME; Bethune MT; Fischer S; Yang X; Gomez-Eerland R; Bingham DB; Sibener LV; Fernandes RA; Velasco A; Baltimore D; Schumacher TN; Khatri P; Quake SR; Davis MM; Garcia KC
Cell; 2018 Jan; 172(3):549-563.e16. PubMed ID: 29275860
[TBL] [Abstract][Full Text] [Related]
12. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer.
Ichiki Y; Takenoyama M; Mizukami M; So T; Sugaya M; Yasuda M; So T; Hanagiri T; Sugio K; Yasumoto K
J Immunol; 2004 Apr; 172(8):4844-50. PubMed ID: 15067062
[TBL] [Abstract][Full Text] [Related]
14. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
Ito D; Visus C; Hoffmann TK; Balz V; Bier H; Appella E; Whiteside TL; Ferris RL; DeLeo AB
Int J Cancer; 2007 Jun; 120(12):2618-24. PubMed ID: 17294448
[TBL] [Abstract][Full Text] [Related]
15. Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells.
Liu X; Peralta EA; Ellenhorn JD; Diamond DJ
Cancer Res; 2000 Feb; 60(3):693-701. PubMed ID: 10676655
[TBL] [Abstract][Full Text] [Related]
16. Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens.
Parikh AY; Masi R; Gasmi B; Hanada KI; Parkhurst M; Gartner J; Sindiri S; Prickett T; Robbins P; Zacharakis N; Beshiri M; Kelly K; Rosenberg SA; Yang JC
Cancer Immunol Immunother; 2023 Oct; 72(10):3149-3162. PubMed ID: 37368077
[TBL] [Abstract][Full Text] [Related]
17. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site.
Azuma K; Shichijo S; Maeda Y; Nakatsura T; Nonaka Y; Fujii T; Koike K; Itoh K
Cancer Res; 2003 Feb; 63(4):854-8. PubMed ID: 12591737
[TBL] [Abstract][Full Text] [Related]
18. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product.
Huang J; El-Gamil M; Dudley ME; Li YF; Rosenberg SA; Robbins PF
J Immunol; 2004 May; 172(10):6057-64. PubMed ID: 15128789
[TBL] [Abstract][Full Text] [Related]
19. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas.
Gnjatic S; Cai Z; Viguier M; Chouaib S; Guillet JG; Choppin J
J Immunol; 1998 Jan; 160(1):328-33. PubMed ID: 9551988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
